tbc-11251 has been researched along with risedronic acid in 1 studies
| Studies (tbc-11251) | Trials (tbc-11251) | Recent Studies (post-2010) (tbc-11251) | Studies (risedronic acid) | Trials (risedronic acid) | Recent Studies (post-2010) (risedronic acid) |
|---|---|---|---|---|---|
| 167 | 32 | 58 | 1,318 | 290 | 487 |
| Protein | Taxonomy | tbc-11251 (IC50) | risedronic acid (IC50) |
|---|---|---|---|
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.1104 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.1699 | |
| Farnesyl diphosphate synthase | Toxoplasma gondii | 0.074 | |
| Farnesyl diphosphate synthase | Trypanosoma cruzi | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for tbc-11251 and risedronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |